Surrozen Pauses Early-Stage Ulcerative Colitis Study Due To Liver Associated Adverse Events

Tucked in its Q3 earnings release on Monday afternoon, Surrozen Inc SRZN voluntarily paused enrollment in the single ascending dose (SAD) portion of its Phase 1 trial evaluating SZN-1326 in healthy volunteers following the observation of treatment-related adverse events.
SZN-1326 is a Wnt mimetic bi-specific antibody that selectively activates the Wnt pathway and is in development for ulcerative colitis.
Several subjects experienced asymptomatic liver transaminase elevations (elevated liver enzymes), including three subjects with grade 3 ALT and AST elevations.
Related: Surrozen Inks Strategic Partnership With Boehringer Ingelheim For Retinal Disease Candidate.
Elevated levels of either of these enzymes are potential indicators of liver damage or liver disease.
There were no corresponding increases in total bilirubin nor any changes in liver function markers such as coagulation markers or albumin.
No other clinically significant laboratory abnormalities were observed, and the transaminase elevations resolved spontaneously in all subjects.
No serious adverse events were observed during the study.
Price Action: SRZN shares closed 30.2% lower at $1.25 on Tuesday.

Earnings Calendar